Advertisement

Pharmacists’ influence on adverse reactions to warfarin: a randomised controlled trial in elderly rural patients

  • Slaven FalamićEmail author
  • Marko Lucijanić
  • Maja Ortner-Hadžiabdić
  • Srećko Marušić
  • Vesna Bačić-Vrca
Research Article
  • 48 Downloads

Abstract

Background Adverse reactions to warfarin may be serious and can lead to hospitalisation or death. Minimising the risk of adverse drug reactions through the intervention of community pharmacists is important for patients receiving warfarin, especially for elderly (≥ 65 years) patients living in rural areas. Objective To evaluate the impact of an intervention by community pharmacists on the risk of adverse drug reactions in elderly rural patients receiving warfarin. Setting: A community pharmacy in a rural area of Croatia. Method We conducted a prospective randomised trial. Eligible patients were recruited at the pharmacy and randomised into one of two groups. The participants were followed up every month for 6 months. Main outcome measure: The incidence and type of adverse drug reactions caused by warfarin and the time-to-event. Results In total, 140 patients were randomized and 131 patients completed the study; 65 patients were in the intervention group. The median age of patients was 73 years of age. The cumulative incidence of adverse drug reactions was significantly lower in the intervention group (6-months rate 29% vs. 85% for intervention and control, respectively; hazard ratio = 0.17, p < 0.001) than in the control group. Factors multivariately associated with the development of adverse drug reactions related to warfarin (p < 0.05) were the absence of pharmaceutical intervention, higher time in therapeutic range, change of warfarin dose, changes in dietary vitamin K intake, and marital status other than married. Conclusion Overall, the pharmacist’s intervention significantly prolonged the time to occurrence of adverse drug reactions and reduced their incidence.

Keywords

Adverse drug reactions Croatia Elderly Pharmacists’ intervention Rural population Warfarin 

Notes

Acknowledgements

This study is a part of the Ph.D. thesis of the first author. The authors would like to acknowledge all the general practitioners responsible for the study participants for the provision of the required data.

Funding

This study was self-funded.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol. 2018;74:819–32.CrossRefGoogle Scholar
  2. 2.
    Pirmohamed M, Scott AK, Green C, Farrar K, Park BK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9.CrossRefGoogle Scholar
  3. 3.
    Kim MM, Metlay J, Cohen A, et al. Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults. Pharmacoepidemiol Drug Saf. 2010;19(7):731–6.CrossRefGoogle Scholar
  4. 4.
    Mearns ES, White CM, Kohn CG, Hawthorne J, Song J-S, Meng J, et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J. 2014;12:14.CrossRefGoogle Scholar
  5. 5.
    Hanlon JT, Pieper CF, Hajjar ER, Sloane RJ, Lindblad CI, Ruby CM, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci. 2006;61(5):511–5.CrossRefGoogle Scholar
  6. 6.
    Manji I, Pastakia SD, Do AN, Ouma MN, Schellhase E, Karwa R, et al. Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya. J Thromb Haemost. 2011;9:2215–20.CrossRefGoogle Scholar
  7. 7.
    Young S, Bishop L, Twells L, Dillon C, Hawboldt J, O’Shea P, et al. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. BMC Fam Pract. 2011;12:88.CrossRefGoogle Scholar
  8. 8.
    Falamić S, Lucijanić M, Hadžiabdić MO, Marušić S, Bačić Vrca V. Pharmacist’s interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial. Int J Clin Pharm. 2018;40(5):1078–85.CrossRefGoogle Scholar
  9. 9.
    Singh S, Bajorek B. Defining, “elderly” in clinical practice guidelines for pharmacotherapy. Pharm Pract (Granada). 2014;12(4):489.CrossRefGoogle Scholar
  10. 10.
    Brezzi M, Dijkstra L, Ruiz V. OECD extended regional typology: the economic performance of remote rural regions. OECD Regional Development Working Papers, 2011/06, OECD Publishing. http://dx.doi.org/10.1787/5kg6z83tw7f4-en Accessed 15 May 2019.
  11. 11.
    Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–37.CrossRefGoogle Scholar
  12. 12.
    Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.CrossRefGoogle Scholar
  13. 13.
    Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.CrossRefGoogle Scholar
  14. 14.
    Franco V, Polanczyk CA, Clausell N. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med. 2004;116(10):651–6.CrossRefGoogle Scholar
  15. 15.
    Franceschi M, Scarcelli C, Niro V, Seripa D, Pazienza AM, Pepe G, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a Geriatric Unit: a prospective study of 1756 patients. Drug Saf. 2008;31:545–56.CrossRefGoogle Scholar
  16. 16.
    Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736–47.CrossRefGoogle Scholar
  17. 17.
    Lucijanic M, Skelin M, Lucijanic T. Survival analysis, more than meets the eye. Biochem Med (Zagreb). 2017;27(1):14–8.CrossRefGoogle Scholar
  18. 18.
    Lucijanić M. Survival analysis in clinical practice: analyze your own data using an Excel workbook. Croat Med J. 2016;57(1):77–9.CrossRefGoogle Scholar
  19. 19.
    Saokaew S, Sapoo U, Nathisuwan S, Chaiyakunapruk N, Permsuwan U. Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. Int J Clin Pharm. 2012;34(1):105–12.CrossRefGoogle Scholar
  20. 20.
    Daniels PR, Manning DM, Moriarty JP, Bingener-Casey J, Ou NN, O’Meara JG, et al. Improving inpatient warfarin therapy safety using a pharmacist-managed protocol. BMJ Open Qual. 2018;7:e000290.CrossRefGoogle Scholar
  21. 21.
    Lee T, Davis E, Kielly J. Clinical impact of a pharmacist-led inpatient anticoagulation service: a review of the literature. Integr Pharm Res Pract. 2016;5:53–63.CrossRefGoogle Scholar
  22. 22.
    Airee A, Guirguis AB, Mohammad RA. Clinical outcomes and pharmacists’ acceptance of a community hospital’s anticoagulation management service utilizing decentralized clinical staff pharmacists. Ann Pharmacother. 2009;43(4):621–8.CrossRefGoogle Scholar
  23. 23.
    Damaske DL, Baird RW. Development and implementation of a pharmacist-managed inpatient warfarin protocol. Proc (Bayl Univ Med Cent). 2005;18(4):397–400.CrossRefGoogle Scholar
  24. 24.
    Tschol N, Lai DK, Tilley JA, Wong H, Brown GR. Comparison of physician- and pharmacist-managed warfarin sodium treatment in open heart surgery patients. Can J Cardiol. 2003;19(12):1413–7.Google Scholar
  25. 25.
    Chilipko AA, Norwood DK. Evaluating warfarin management by pharmacists in a community teaching hospital. Consult Pharm. 2014;29(2):95–103.CrossRefGoogle Scholar
  26. 26.
    Schillig J, Kaatz S, Hudson M, Krol GD, Szandzik EG, Kalus JS. Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med. 2011;6(6):322–8.CrossRefGoogle Scholar
  27. 27.
    Burns N. Evaluation of warfarin dosing by pharmacists for elderly medical in-patients. Pharm World Sci. 2004;26(4):232–7.CrossRefGoogle Scholar
  28. 28.
    Rivey MP, Wood RD, Allington DR, Stratton TP, Erickson CC, Stenson TA. Pharmacy-managed protocol for warfarin use in orthopedic surgery patients. Am J Health Syst Pharm. 1995;52(12):1310–6.CrossRefGoogle Scholar
  29. 29.
    Manzoor BS, Cheng WH, Lee JC, Uppuluri EM, Nutescu EA. Quality of pharmacist-managed anticoagulation therapy in long-term ambulatory settings: a systematic review. Ann Pharmacother. 2017;51:1122–37.CrossRefGoogle Scholar
  30. 30.
    Harper P, Mcmichael I, Griffiths D, Harper J, Hill C. The community pharmacy-based anticoagulation management service achieves a consistently high standard of anticoagulant care. N Z Med J. 2015;128(1422):31–41.Google Scholar
  31. 31.
    Stafford L, Peterson GM, Bereznicki LR, et al. Clinical outcomes of a collaborative, home-based postdischarge warfarin management service. Ann Pharmacother. 2011;45(3):325–34.CrossRefGoogle Scholar
  32. 32.
    Knežević A, Nadinić M, Užović Frakin I, Trkulja V. Poor warfarin anticoagulation in long-term thromboprophylaxis: a survey in a southern Croatian county. Croat Med J. 2019;60(1):2–11.CrossRefGoogle Scholar
  33. 33.
    Costa GLDB, Lamego RM, Colosimo EA, Valacio RA, Moreira MDCV. Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study. Clin Ther. 2012;34(7):1511–20.CrossRefGoogle Scholar
  34. 34.
    Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis. PLoS ONE. 2017;12(11):e0188482.CrossRefGoogle Scholar
  35. 35.
    Marusic S, Bacic-Vrca V, Obreli Neto PR, Franic M, Erdeljic V, Gojo-Tomic N. Actual drug-drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol. 2013;69:1717–24.CrossRefGoogle Scholar
  36. 36.
    Urbonas G, Valius L, Šakalytė G, Petniūnas K, Petniūnienė I. The quality of anticoagulation therapy among warfarin-treated patients with atrial fibrillation in a primary health care setting. Medicina (Kaunas). 2019;55(1):1–15.Google Scholar
  37. 37.
    Zhang J, Liu M, Chen Q, Wu J, Cao H. Outcomes of an online pharmacist-managed anticoagulation clinic for individuals on warfarin therapy living in rural communities. Thromb Res. 2017;157:136–8.CrossRefGoogle Scholar
  38. 38.
    Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Pharmacy Branka MarušićDonji MiholjacCroatia
  2. 2.Hematology DepartmentUniversity Hospital DubravaZagrebCroatia
  3. 3.Centre for Applied Pharmacy, Faculty of Pharmacy and BiochemistryUniversity of ZagrebZagrebCroatia
  4. 4.Department of Clinical PharmacologyUniversity Hospital DubravaZagrebCroatia
  5. 5.Department of Clinical PharmacyUniversity Hospital DubravaZagrebCroatia

Personalised recommendations